
Decision Diagnostics Corp. has submitted 2 applications with the FDA for a COVID-19 testing technology that the firm claims can identify the virus in about 10 seconds.
Decision Diagnostics Corp. has submitted 2 applications with the FDA for a COVID-19 testing technology that the firm claims can identify the virus in about 10 seconds.
New research presented at ERS shows how critically ill COVID-19 patients face cardiac and pulmonary burdens weeks after recovery.
The investigational vaccine was regarded as well-tolerated and elicited an immune response.
A new study that compared the results of a behavior intervention program for young adults living with HIV found outcomes were better when the intervention occurred in a clinic rather than at the patients’ homes.
A Rapid Response in BMJ argues that to achieve Zero-COVID, we need to broaden our thinking to include the controlled and careful acquisition of population immunity.
In this segment, Dysphagia expert Rinki Varindani Desai shares her perspective on the need for an adaptive health care system response that incorporates equity across health burdens.
How a Chicago-based surgeon managed an unprecedented procedure for young woman at the height of the pandemic.
An examination of a patient presenting with the condition in the early days of the pandemic without the access to current care protocols.
SARS-CoV-2 is unlikely to pass through the breast milk of infected mothers to their infants, according to a recent evaluation of breast milk samples from 18 women who tested positive for the COVID-19.
The CMS Sepsis Bundle Core Performance Measure of sepsis treatment could contribute to the overuse of broad-spectrum antibiotics
A new report shows a UK-based participant experienced a serious adverse event, but is anticipated to recover.
A total of 9 firms signed the letter promising to put safety at the top of the priority list in ongoing COVID-19 vaccine development projects.
Rising costs from 2014-2018 may have hindered PrEP expansion, according to a recent retrospective study.
A follow-up on analysis from earlier in the pandemic reveals that virulence in children remained stable over a 5-month period.
The story of an early-infected US physician who launched a non-profit, participated in trials, and guided her peers after overcoming infection.
An observational study in the United Kingdom supports the concepts of a hyperinflammation phenotype for severe COVID-19 cases and could help guide risk assessment, precision medicine, and trial design.
In looking at enhancing intervention efforts, where should we do them?
The 2-step algorithm for diagnosing Clostridioides difficile infection is difficult to interpret in patients who have cancer or are immunocompromised.
A new study sought to quantify the impacts of various testing strategies. It found rapid testing and self-isolation were the most critical factors.
Weekly, we identify which FDA recall announcements might be most clinically relevant.
The following is a quick review of the week’s top FDA approvals and authorizations.
The phase 1/2 findings show the recently regulated two-dose vaccine was associated with no serious adverse events and antibody response within 21 days.
At a time when schools and college campuses have reopened, an expert discusses adolescents' trends in spreading COVID-19 more easily, and the lack of testing available to them.
This test simultaneously detects and differentiates between SARS-CoV-2, influenza A and B.
Frontline health care workers had a nearly 12 times higher risk of testing positive for COVID-19 compared with individuals in the general community.
JAMA Internal Medicine study focused on patients with mild disease.
A review of the week's top infectious disease news, including links established between mental health and pursuit of need medical care during COVID-19.
How children and adolescents contract, spread, and suffer through the virus differently than other age groups.
New study suggests a connection between widespread mental health challenges and the decline in care during COVID-19.
If phase 1/2 data is positive, the companies plan to move into phase 3 by December.